



Attorney Docket No.: 3167/12

PATENT

TECH CENTER 1600/2900

NOV 05 2002

RECEIVED

YCB
A-5
11-19a

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of)
John P. McKearn et al.) Group Art Unit: 1614
Serial No. 09/843,132) Examiner: J. Goldberg
Filed: April 25, 2001) Date: October 29, 2002
Title: ANTIANGIOGENIC COMBINATION THERAPY FOR THE
TREATMENT OF CANCER

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Commissioner of Patents and Trademarks,
Washington D.C., 20231 on October 29, 2002
Sharon Rudebeck

Sharon Rudebeck Date: 10/29/02

Honorable Commissioner of Patents
Washington, D.C.

Sir:

AMENDMENT

In response to the Office Action mailed October 4, 2002, having a shortened statutory period of one month, expiring November 4, 2002, please amend the above referenced application as follows:

IN THE CLAIMS

Please cancel Claims 140-181 without prejudice.

RESTRICTION

The present Office Action restricts the invention to Group 1: Claims 1-139 drawn to composition and method for treating neoplasms in a host employing an enhanced combination of a DNA topoisomerase I inhibitor and a COX-2 inhibitor; or Group II, Claims 140-181 drawn to a method for treating DNA topoisomerase I inhibiting agent-related diarrhea in a host by administering a COX-2 inhibitor.

ELECTION

In response to the restriction, Applicants elect Group I without traverse.

Applicants cancel Claims 140-181 without prejudice.